Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dapagliflozin 5mg Clear all
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 4 Interventional Results available

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

NCT02796170
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 23, 2026, 7:06 PM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

NCT04899349
View directory record Official record
Conditions
Breast Cancer
Interventions
Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

NCT03199053
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

NCT02681094
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Saraland, Alabama • Fresno, California • Harbor City, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 23, 2026, 7:06 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

NCT03660683
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
30 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

NCT00673231
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Fresno, California • Greenbrae, California • Roswell, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

NCT01662999
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 23, 2026, 7:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

NCT02551874
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

NCT02338193
View directory record Official record
Conditions
Diabetes Prevention in Women After GDM Who Are at High-risk
Interventions
DAPA/MET XR, DAPA, MET XR
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

NCT01606007
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
80
States / cities
Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Not applicable Interventional Results available

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

NCT02613897
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 23, 2026, 7:06 PM EDT
Completed Phase 1 Interventional

Dapagliflozin Effects on Hypoglycemia

NCT03704818
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Dapagliflozin 5mg, Placebo Oral Tablet
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 23, 2026, 7:06 PM EDT
Active, not recruiting Phase 3 Interventional

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

NCT04333823
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Dapagliflozin 5mg, Placebo
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 23, 2026, 7:06 PM EDT